nodes	percent_of_prediction	percent_of_DWPC	metapath
Masoprocol—IGF1R—Stabilization and expansion of the E-cadherin adherens junction—HGF—bile duct cancer	0.031	0.0366	CbGpPWpGaD
Masoprocol—IGF1R—pancreas—bile duct cancer	0.028	0.183	CbGeAlD
Masoprocol—IGF1R—Stabilization and expansion of the E-cadherin adherens junction—MET—bile duct cancer	0.0244	0.0288	CbGpPWpGaD
Masoprocol—IGF1R—Integrins in angiogenesis—TGFBR2—bile duct cancer	0.0244	0.0288	CbGpPWpGaD
Masoprocol—IGF1R—TSH signaling pathway—GNAS—bile duct cancer	0.0226	0.0267	CbGpPWpGaD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—MET—bile duct cancer	0.0219	0.0259	CbGpPWpGaD
Masoprocol—LTB4R—liver—bile duct cancer	0.0216	0.141	CbGeAlD
Masoprocol—IGF1R—Plasma membrane estrogen receptor signaling—MMP2—bile duct cancer	0.0208	0.0245	CbGpPWpGaD
Masoprocol—IGF1R—SHC-related events triggered by IGF1R—NRAS—bile duct cancer	0.0206	0.0243	CbGpPWpGaD
Masoprocol—ALOX5—Eicosanoid Synthesis—PTGS2—bile duct cancer	0.0179	0.0211	CbGpPWpGaD
Masoprocol—IGF1R—liver—bile duct cancer	0.0178	0.116	CbGeAlD
Masoprocol—IGF1R—SHC-related events triggered by IGF1R—KRAS—bile duct cancer	0.0177	0.0209	CbGpPWpGaD
Masoprocol—LTB4R—lymph node—bile duct cancer	0.0166	0.108	CbGeAlD
Masoprocol—IGF1R—Plasma membrane estrogen receptor signaling—MMP9—bile duct cancer	0.0156	0.0184	CbGpPWpGaD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—SMAD4—bile duct cancer	0.0153	0.0181	CbGpPWpGaD
Masoprocol—IGF1R—SHC-related events triggered by IGF1R—HRAS—bile duct cancer	0.015	0.0178	CbGpPWpGaD
Masoprocol—ALOX5—pancreas—bile duct cancer	0.015	0.0977	CbGeAlD
Masoprocol—IGF1R—Focal Adhesion—TNC—bile duct cancer	0.0147	0.0174	CbGpPWpGaD
Masoprocol—IGF1R—SHC-related events triggered by IGF1R—IL6—bile duct cancer	0.0144	0.017	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—MET—bile duct cancer	0.0143	0.0169	CbGpPWpGaD
Masoprocol—IGF1R—Plasma membrane estrogen receptor signaling—NRAS—bile duct cancer	0.0138	0.0164	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.0138	0.0163	CbGpPWpGaD
Masoprocol—IGF1R—lymph node—bile duct cancer	0.0137	0.0893	CbGeAlD
Masoprocol—IGF1R—IGF1 pathway—HRAS—bile duct cancer	0.013	0.0154	CbGpPWpGaD
Masoprocol—IGF1R—Stabilization and expansion of the E-cadherin adherens junction—EGFR—bile duct cancer	0.0124	0.0146	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.0123	0.0145	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—NOS2—bile duct cancer	0.0122	0.0144	CbGpPWpGaD
Masoprocol—CYP2J2—liver—bile duct cancer	0.0121	0.0789	CbGeAlD
Masoprocol—IGF1R—Plasma membrane estrogen receptor signaling—KRAS—bile duct cancer	0.0119	0.0141	CbGpPWpGaD
Masoprocol—CYP2J2—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.0111	0.0132	CbGpPWpGaD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—bile duct cancer	0.0111	0.0131	CbGpPWpGaD
Masoprocol—IGF1R—Endochondral Ossification—MMP9—bile duct cancer	0.0109	0.0129	CbGpPWpGaD
Masoprocol—IGF1R—SHP2 signaling—NRAS—bile duct cancer	0.0105	0.0124	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—ERBB2—bile duct cancer	0.0105	0.0123	CbGpPWpGaD
Masoprocol—IGF1R—Plasma membrane estrogen receptor signaling—HRAS—bile duct cancer	0.0101	0.012	CbGpPWpGaD
Masoprocol—ALOX5—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.00993	0.0117	CbGpPWpGaD
Masoprocol—IGF1R—SHP2 signaling—EGFR—bile duct cancer	0.00956	0.0113	CbGpPWpGaD
Masoprocol—ALOX5—liver—bile duct cancer	0.00953	0.0622	CbGeAlD
Masoprocol—IGF1R—Focal Adhesion—HGF—bile duct cancer	0.00926	0.0109	CbGpPWpGaD
Masoprocol—IGF1R—SHP2 signaling—KRAS—bile duct cancer	0.00903	0.0107	CbGpPWpGaD
Masoprocol—IGF1R—Endochondral Ossification—TGFB1—bile duct cancer	0.00901	0.0106	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—PTGS2—bile duct cancer	0.00898	0.0106	CbGpPWpGaD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—bile duct cancer	0.00893	0.0105	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—NRAS—bile duct cancer	0.00795	0.00939	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—MMP9—bile duct cancer	0.00788	0.00931	CbGpPWpGaD
Masoprocol—IGF1R—SHP2 signaling—HRAS—bile duct cancer	0.00767	0.00906	CbGpPWpGaD
Masoprocol—IGF1R—IRS-related events triggered by IGF1R—NRAS—bile duct cancer	0.00745	0.0088	CbGpPWpGaD
Masoprocol—IGF1R—SHP2 signaling—IL6—bile duct cancer	0.00735	0.00868	CbGpPWpGaD
Masoprocol—ALOX5—lymph node—bile duct cancer	0.00731	0.0477	CbGeAlD
Masoprocol—IGF1R—Focal Adhesion—MET—bile duct cancer	0.0073	0.00862	CbGpPWpGaD
Masoprocol—IGF1R—IGF1R signaling cascade—NRAS—bile duct cancer	0.00725	0.00857	CbGpPWpGaD
Masoprocol—IGF1R—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—bile duct cancer	0.00725	0.00856	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—EGFR—bile duct cancer	0.00725	0.00856	CbGpPWpGaD
Masoprocol—IGF1R—TSH signaling pathway—HRAS—bile duct cancer	0.00692	0.00817	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—KRAS—bile duct cancer	0.00684	0.00808	CbGpPWpGaD
Masoprocol—CYP19A1—liver—bile duct cancer	0.00659	0.043	CbGeAlD
Masoprocol—LTB4R—Spinal Cord Injury—TGFB1—bile duct cancer	0.0065	0.00767	CbGpPWpGaD
Masoprocol—IGF1R—IRS-related events triggered by IGF1R—KRAS—bile duct cancer	0.00641	0.00757	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—EGFR—bile duct cancer	0.00637	0.00752	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00632	0.00747	CbGpPWpGaD
Masoprocol—ALOX5—Selenium Micronutrient Network—PTGS2—bile duct cancer	0.00632	0.00746	CbGpPWpGaD
Masoprocol—IGF1R—IGF1R signaling cascade—KRAS—bile duct cancer	0.00624	0.00737	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—FAR2—bile duct cancer	0.00613	0.00725	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—TP53—bile duct cancer	0.00608	0.00718	CbGpPWpGaD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—TGFB1—bile duct cancer	0.00606	0.00716	CbGpPWpGaD
Masoprocol—IGF1R—Apoptosis—TP53—bile duct cancer	0.00597	0.00705	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—GNAS—bile duct cancer	0.00584	0.00689	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—HRAS—bile duct cancer	0.00582	0.00687	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.00578	0.00683	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—FAR2—bile duct cancer	0.00547	0.00646	CbGpPWpGaD
Masoprocol—IGF1R—IRS-related events triggered by IGF1R—HRAS—bile duct cancer	0.00545	0.00643	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—TP53—bile duct cancer	0.00535	0.00631	CbGpPWpGaD
Masoprocol—IGF1R—Focal Adhesion—ERBB2—bile duct cancer	0.00534	0.0063	CbGpPWpGaD
Masoprocol—IGF1R—IGF1R signaling cascade—HRAS—bile duct cancer	0.00531	0.00627	CbGpPWpGaD
Masoprocol—IGF1R—IRS-related events triggered by IGF1R—IL6—bile duct cancer	0.00521	0.00616	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.00516	0.00609	CbGpPWpGaD
Masoprocol—IGF1R—IGF1R signaling cascade—IL6—bile duct cancer	0.00508	0.006	CbGpPWpGaD
Masoprocol—CYP19A1—lymph node—bile duct cancer	0.00505	0.033	CbGeAlD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—TP53—bile duct cancer	0.00499	0.0059	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—IL6—bile duct cancer	0.00489	0.00578	CbGpPWpGaD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—HRAS—bile duct cancer	0.00477	0.00564	CbGpPWpGaD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—IL6—bile duct cancer	0.00457	0.0054	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.00433	0.00511	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bile duct cancer	0.00408	0.00482	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—RNF43—bile duct cancer	0.00401	0.00474	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.00394	0.00465	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—SMAD4—bile duct cancer	0.00386	0.00456	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.00372	0.0044	CbGpPWpGaD
Masoprocol—IGF1R—Focal Adhesion—EGFR—bile duct cancer	0.0037	0.00437	CbGpPWpGaD
Masoprocol—ALOX5—Selenium Micronutrient Network—IL6—bile duct cancer	0.00344	0.00407	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—RNF43—bile duct cancer	0.00341	0.00403	CbGpPWpGaD
Masoprocol—IGF1R—Insulin Signaling—HRAS—bile duct cancer	0.00341	0.00402	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—GNAS—bile duct cancer	0.0033	0.0039	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.00316	0.00374	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.00303	0.00358	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—IDH2—bile duct cancer	0.003	0.00354	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—GNAS—bile duct cancer	0.003	0.00354	CbGpPWpGaD
Masoprocol—IGF1R—Focal Adhesion—HRAS—bile duct cancer	0.00297	0.00351	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—FAR2—bile duct cancer	0.00282	0.00333	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—IDH2—bile duct cancer	0.00267	0.00315	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.00266	0.00314	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—IDH1—bile duct cancer	0.00258	0.00304	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—IDH1—bile duct cancer	0.0023	0.00271	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—TGFBR2—bile duct cancer	0.00183	0.00217	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—GNAS—bile duct cancer	0.00177	0.00209	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—SMAD4—bile duct cancer	0.00174	0.00205	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—SLC5A5—bile duct cancer	0.0017	0.00201	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.00159	0.00188	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—TGFBR2—bile duct cancer	0.00156	0.00184	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—SLC5A5—bile duct cancer	0.00151	0.00179	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—GNAS—bile duct cancer	0.0015	0.00178	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.0015	0.00177	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—SMAD4—bile duct cancer	0.00148	0.00174	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.00142	0.00168	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.00142	0.00167	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—IDH2—bile duct cancer	0.00138	0.00162	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—GNAS—bile duct cancer	0.00132	0.00156	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.00126	0.00149	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—NRAS—bile duct cancer	0.00125	0.00148	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—IDH1—bile duct cancer	0.00118	0.0014	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—GNAS—bile duct cancer	0.00118	0.00139	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—EGFR—bile duct cancer	0.00114	0.00135	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—KRAS—bile duct cancer	0.00108	0.00127	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—ERBB2—bile duct cancer	0.000972	0.00115	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—HRAS—bile duct cancer	0.000916	0.00108	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—IL6—bile duct cancer	0.000876	0.00104	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—MMP9—bile duct cancer	0.000834	0.000985	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—ERBB2—bile duct cancer	0.000826	0.000976	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—SLC5A5—bile duct cancer	0.00078	0.000922	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—NRAS—bile duct cancer	0.000739	0.000873	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000731	0.000864	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—PTGS2—bile duct cancer	0.000709	0.000838	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—MMP9—bile duct cancer	0.000709	0.000837	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—TGFB1—bile duct cancer	0.000687	0.000811	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—EGFR—bile duct cancer	0.000674	0.000796	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—KRAS—bile duct cancer	0.000636	0.000752	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—PTGS2—bile duct cancer	0.000632	0.000747	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—NRAS—bile duct cancer	0.000629	0.000743	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—GNAS—bile duct cancer	0.000606	0.000716	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—TGFB1—bile duct cancer	0.000584	0.00069	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—EGFR—bile duct cancer	0.000573	0.000676	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—TP53—bile duct cancer	0.000566	0.000668	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—KRAS—bile duct cancer	0.000541	0.000639	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—HRAS—bile duct cancer	0.000541	0.000639	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—IL6—bile duct cancer	0.000518	0.000611	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—TP53—bile duct cancer	0.000481	0.000568	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—HRAS—bile duct cancer	0.00046	0.000543	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—IL6—bile duct cancer	0.00044	0.00052	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—PTGS2—bile duct cancer	0.000326	0.000385	CbGpPWpGaD
